A common side effect of treatment with inhibitors of angiogenesis is arterial hypertension,36 and Sunshine et al.16 proposed that co-administration of endostatin during antiangiogenesis therapy, e.g. VEGF inhibitors, may prevent the drug-induced hypertension. This evidence concerns the gene COL18A1 and Hypertension.